NASDAQ:BTAI

Bioxcel Therapeutics Stock News

Healthcare > Biotechnology

Buy BTAI

*Your capital is at risk

$1.26

-0.0400 (-3.08%)

At Close: Jun 23, 2026

The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions

12:00am, Thursday, 18'th Jun 2020

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) Adverum Biotechnologies Inc...

3 “Strong Buy” Pharmaceutical Stocks With Major Catalysts Approaching

01:43pm, Wednesday, 17'th Jun 2020

Even during economic downturns, one fact remains resolute: pharma stocks represent the ultimate risk/reward plays. Out on Wall Street, the sector has become known for its high volatility. How did it e

BioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial Officer

11:00am, Tuesday, 16'th Jun 2020

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-o

The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO

12:00am, Tuesday, 16'th Jun 2020

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Applied Molecular Transport...

BioXcel Therapeutics to Participate in Two Upcoming Investor Conferences

08:05pm, Monday, 15'th Jun 2020

NEW HAVEN, Conn., June 15, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.

Analysts Offer Insights on Healthcare Companies: CytoDyn (Other OTC: CYDY), Bioxcel Therapeutics (NASDAQ: BTAI) and SLANG Worldwide (Other OTC: SLGWF) - Markets

10:14am, Friday, 12'th Jun 2020

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CytoDyn (CYDY

BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms

11:00am, Thursday, 11'th Jun 2020

The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid

12:00am, Friday, 05'th Jun 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 4) Biohaven Pharmaceutical...

Benzinga's Top Upgrades, Downgrades For June 4, 2020

01:42pm, Thursday, 04'th Jun 2020

Upgrades * For American Eagle Outfitters Inc (NYSE: AEO), Morgan Stanley upgraded the stock from Underweight to Equal-Weight. For the first quarter, American Eagle Outfitters had an EPS of ($0.84),

BioXcel Therapeutics to Present at the Jefferies Virtual Healthcare Conference

11:00am, Thursday, 28'th May 2020

NEW HAVEN, Conn., May 28, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.

The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

12:00am, Wednesday, 20'th May 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ADC Therapeutics SA (NYSE:...

The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering

12:00am, Tuesday, 19'th May 2020

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE:...

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by